Abstract: Although the majority of smooth muscle neoplasms found in the uterus are benign, uterine leiomyosarcoma (LMS) is extremely malignant, with high rates of recurrence and metastasis. The development of gynecologic tumors is often correlated with secretion of female hormone; however, the development of human uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are unclearly understood.
Abstract: Although the majority of smooth muscle neoplasms found in the uterus are benign, uterine leiomyosarcoma (LMS) is extremely malignant, with high rates of recurrence and metastasis. The development of gynecologic tumors is often correlated with secretion of female hormone; however, the development of human uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are unclearly understood.
Importantly, a diagnostic-biomarker, which distinguishes malignant human uterine LMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with human uterine LMS, in order to establish a clinical treatment method. Homozygous deficient mice for a proteasome subunit 1i/LMP2 spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age.
Defective LMP2 expression in human uterine LMS was demonstrated, but present in human LMA. Therefore, loss in LMP2 expression may be one of the risk factors for human uterine LMS. LMP2 may be a potential diagnostic-biomarker and targeted-molecule for a new therapeutic approach.
Introduction:
The uterus, the organ in which the embryo grows, is composed of three layers, the uterine endometrium, myometrium and a serous membrane enveloping the uterus, the myometrium is composed of smooth muscle. In general, the term uterine tumor refers to an epithelial malignant tumor of the uterus, which is roughly classified as a tumor of the uterine cervix or the uterine body. Because of the prevalence of screening, uterine cervix cancer is decreasing in incidence, and usually detected at an early stage. In contrast, cancer of the uterine body is increasing in incidence, and rarely detected at the initial stages. While most tumors of the uterine body are adenocarcinomas derived from the subintimal gland, tumors of the uterine cervix are classified into squamous cancer and adenocarcinoma. Smooth muscle tumors which develop in the myometrium have been traditionally divided into benign LMA and malignant LMS based on cytological atypia, mitotic activity and other criteria. Uterine LMS is a rare gynecologic malignancy in the female genital tract, having an estimated annual incidence of 0.64 per 100,000 women 1 . Uterine LMS accounts for 5% of tumors of the uterine body and develops more often in the muscle layer of the uterine body than in the uterine cervix 2, 3 . Distinguishing uterine LMA from LMS is very difficult, and a diagnosis generally requires surgery and cytoscopy.
A main factor in the development of tumors in the uterine body is the hormonal developing an efficient adjuvant therapy is expected to improve the prognosis of the disease [5] [6] [7] .
The identification of a risk factor associated with the development of uterine LMS would significantly contribute to the development of preventive and therapeutic treatments.
Development of malignant uterine tumor in LMP2-deficient mice:
Cytoplasmic proteins are mostly degraded by a protease complex, which has many substrates consisting of twenty-eight 20 to 30-kDa subunits, referred to as the proteasome 8 . The proteasomal degradation pathway is essential for many cellular processes, including the cell cycle, the regulation of gene expression, and others. IFN- up-regulates the expression of large numbers of responsive genes, proteasome's subunits, i.e., LMP2, LMP7, and LMP10 are also markedly induced by IFN- signal [9] [10] [11] [12] [13] . Here we identify LMP2, a single IFN--responsive gene product, as obligatory for tumor surveillance 12 and demonstrate a tissue-specific role for LMP2 in protection from spontaneous neoplasms of the uterus.
The homozygous deficient mice for LMP2 show tissue-and substrate-dependent abnormalities in the biological functions of the proteasome, and impaired functioning of the proteasome in the splenocytes or hepatic cells 14 . We found that uterine LMS occurred in female LMP2-deficient mice at age 6 months or older, and the incidence at 14 months of age was about 40% 15 ( Fig. 1 ). The curve indicating the incidence in mice is very similar to that indicating the incidence of human uterine LMS, which occurs after menopause. Histological studies of LMP2-lacking uterine tumors revealed characteristic abnormalities of uterine LMS 15 . The tumors lacked lymphoid infiltrates, a sign of immune recognition, and consisted of uniform elongated myometrium cells arranged into bundles. The nuclei of the tumor cells varied in size and shape; furthermore, mitosis was frequent, in contrast, the myometrium cells of C57BL/6 mice were normal in appearance 15 . Whereas relatively few Ki-67-positive cells, the proliferating cells of solid tumors, were observed in the basal cell layer of the normal myometrium, most of the basal cells vividly expressed Ki-67 in LMP2-deficient mice 15 . This immunological staining indicates abnormal proliferation of the LMP2-lacking cells in the basal layer 15 . LMP2-deficient mice that have developed uterine LMS undergo considerable weight loss, and then die by 14 months of age 15 ( Fig. 1) . The LMP2-deficient mice also exhibit skeletal muscle metastasis from uterine LMS. Therefore it is like that LMP2-deficient mice with uterine LMS have died of mass effect and metastasis. In general, it is not easy to distinguish uterine LMA from LMS, however, in mice, because of such characteristic pathological findings, significant weight loss, and exhibition of skeletal muscle metastasis, a tumor that develops in the uterus of an LMP2-deficient mouse can be considered malignant,
i.e., a uterine LMS. Definitive histological studies must be performed, including the gene-expression profiling of several known pro-oncogenic factors as well as factors such as brain-specific polypeptide PEP-19 and a transmembrane tyrosine kinase receptor, C-kit [33] [34] [35] . The reduced expression of calponin h1 transcripts was reported to be associated with uterine LMS, and calponon h1 7 might function as a tumor suppressor in uterine LMS 36, 37 . A recent study showed that re-expression of human calponin h1 suppressed cell proliferation and tumorigenesis in uterine LMS cells 37 . Further research is required to demonstrate the correlative functions of LMP2
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and other anti-oncogenic factors with calponin h1 in the tumorigenesis of uterine LMS.
Clarification of the correlation between these factors and the development of uterine LMS and the identification of specific risk factors may lead to the development of new treatments for the disease. Uterine LMS is refractory to chemotherapy and has a poor prognosis. The molecular biological and cytological information obtained from LMP2-deficient mice will contribute remarkably to the development of preventive methods, a potential diagnosticbiomarker, and new therapeutic approaches against uterine LMS. LMP2-deficient females, uterine LMS is observed at 6 months of age. The incidence at age 14 months is as high as 40%. The curve indicating the incidence of mouse uterine LMS is very similar of that indicating the incidence of human uterine LMS, which is observed after menopause. In mice with tumors of the uterus, significant weight loss is observed (d). Thus, a tumor that develops in the uterus is diagnosed as malignant, i.e., uterine LMS.
